Investors
Key investment highlights in AlzeCure
- Targeting areas of huge unmet medical needs
- Strong team with extensive experience and track record
- Platforms with first-in-class properties and potential game-changers
- Parallel investments in several candidates and potent follow-up programs
- Multi-billion dollar market opportunity areas
- Phase II company
Press releases
-
AlzeCure to partake in Redeye Theme: Alzheimer on March 21
March 14, 2024
-
AlzeCure presents new preclinical data with NeuroRestore ACD856 at leading Alzheimer’s conference
March 7, 2024
-
AlzeCure publishes clinical results supporting continued development of NeuroRestore ACD856 against Alzheimer’s
March 5, 2024